Daewoong Pharmaceutical History and Business Operations

Daewoong Pharmaceutical has a rich history that spans over 70 years. The company was founded in 1959 by Jung-Sick Lee, a Korean entrepreneur and pharmacist.

Daewoong Pharmaceutical started as a small pharmaceutical company in Seoul, South Korea. It has since grown into a leading pharmaceutical company in Korea with a global presence.

The company's early success can be attributed to its innovative approach to pharmaceutical research and development. Daewoong Pharmaceutical has developed a wide range of pharmaceutical products, including prescription medications and over-the-counter (OTC) products.

Daewoong Pharmaceutical's business operations are focused on developing and marketing innovative pharmaceutical products.

Daewoong Pharmaceutical offers a range of products and services, including over the counter drugs, prescription drugs, and generics.

Their over the counter drugs include Nabota, which is a product that helps with certain health issues.

Their prescription drugs include CareTropin, which is a CDMO service that helps with the production of certain medications.

A different take: Does Background Check Include Credit Check

Daewoong Pharmaceutical also offers a product called Uruso Tab 200mg, which is used to treat conditions such as gallstones and liver disease. This product contains Acid Ursodeoxycholic, which helps to improve liver function and dissolve gallstones.

The company's products also include Siro Ăn Ngon Enzym Kid King Baby, which is a digestive enzyme supplement that helps to reduce symptoms of indigestion and heartburn.

Here is a list of some of their products:

Shawn Park is the CEO and President of Daewoong Pharmaceuticals. He is the driving force behind the company's success.

Daewoong Pharmaceuticals is a leading pharmaceutical company with a strong presence in the market.

If you're in the pharmaceutical industry, you'll need to know the NAICS code for your business. The NAICS code for Daewoong Pharmaceuticals is 32, 325, 32541, and 3254.

The NAICS code system helps businesses and governments classify industries and products. This classification is essential for tax purposes, government regulations, and market research.

On a similar theme: Bank Naics Code

You can use the NAICS code 32 for the manufacturing sector, which is the primary category for pharmaceutical companies like Daewoong Pharmaceuticals. NAICS code 325 is for the chemical manufacturing industry, which is also relevant to pharmaceuticals.

The more specific NAICS codes, 32541 and 3254, classify Daewoong Pharmaceuticals as a manufacturer of pharmaceuticals and medicines.

Daewoong Pharmaceuticals has an SIC code of 283, 28.

The SIC code for Daewoong Pharmaceuticals is specific to the pharmaceutical industry.

Daewoong Pharmaceuticals' SIC codes indicate its classification as a pharmaceutical company.

The SIC code 283 is a general classification for pharmaceuticals and medicine.

The SIC code 28 is a more specific classification for chemicals and allied products.

Daewoong Pharmaceuticals' SIC codes are essential for understanding its business operations and classification.

Take a look at this: 28 Dolar Kaç Türk Lirası

Daewoong Pharmaceutical offers a range of products, including over the counter drugs.

Their Nabota brand is a notable one.

The company's product portfolio includes prescription drugs, such as Uruso Tab 200mg, which is used to treat gallstones rich in cholesterol and improve liver function in primary biliary cirrhosis and hepatitis C.

Uruso Tab 200mg is available in a specific dosage, which varies depending on the individual's condition, so it's essential to consult a doctor before using it.

Some notable services offered by Daewoong Pharmaceutical include CDMO (Contract Development and Manufacturing Organization) services for prescription drugs.

The company's product offerings also include generics, such as Novosis.

Here is a breakdown of Daewoong Pharmaceutical's product and service categories:

Siro Ăn Ngon Enzym Kid King Baby is another notable product from Daewoong Pharmaceutical, used to improve digestion and reduce symptoms such as acid reflux and nausea.

Daewoong Pharmaceutical Co., LTD has achieved numerous milestones in its history. One of the notable achievements is the recognition by the President of Vietnam in 1987 for exporting $2 million.

Daewoong Pharmaceutical Co., LTD has been consistently recognized for its quality management. In 1989, the company received a commendation from the Prime Minister at the National Quality Management Conference.

Here are some of the notable awards received by Daewoong Pharmaceutical Co., LTD:

Daewoong Pharmaceutical Co., LTD has also made significant contributions to the pharmaceutical industry. In 2011, the company opened the first in-house childcare center in the industry, "Trung tâm chăm sóc ban ngày Little Bear".

Daewoong Pharmaceutical Co Ltd is actively involved in clinical trials, with a focus on determining the go-to-market proposition for the company. This involves gaining insight into their clinical operations, recruitment, and trial strategy.

The company has multiple products in various stages of clinical trials, including drugs in Phase 1 and Phase 2 trials. In Phase 2 trials, Daewoong Pharmaceutical Co Ltd has eight products, including dwp-05195, which is undergoing three trials.

Daewoong Pharmaceutical Co Ltd also has a significant presence in Phase 1 trials, with 54 of their products undergoing this stage of clinical testing. One of these products is gemigliptin, which is being tested for its safety and efficacy.

The company's clinical trials cover a range of indications, including cardiovascular diseases, hepatitis, and dry eye syndromes. Daewoong Pharmaceutical Co Ltd is also exploring the use of stem cells in their research, as seen in their trial for umbilical cord mesenchymal stem cells.

Daewoong Pharmaceutical Co Ltd's involvement in clinical trials is a key aspect of their business strategy, allowing them to stay competitive in the market and bring new products to market.

Daewoong Pharmaceuticals has a significant annual revenue. The company's annual revenue was $920.6 million in 2025.

The revenue figure of $920.6 million in 2025 gives us an idea of the company's financial health and stability.

Daewoong Pharmaceuticals' annual revenue was $920.6 million in 2025.

Looking at the financials, you can see that Daewoong Pharmaceuticals had a significant revenue in 2025.

Their annual revenue was indeed $920.6 million that year.

Daewoong Pharmaceutical is a funded company.

The company has received funding from a single institutional investor - Business Innovation Network.

Daewoong Pharmaceutical Co., LTD has a remarkable journey of growth and expansion.

In 2001, Daewoong Pharmaceutical introduced Easyef, a new medication developed with the world's number one biotechnology. This marked a significant milestone for the company.

The company's growth led to a separation from Daewoong in 2002, allowing them to operate independently.

Daewoong Pharmaceutical achieved four major milestones in 2003: obtaining ISO14001 certification for its Hyangnam factory, achieving OHSAS18001 certification for health and safety management, completing a state-of-the-art automated logistics center, and successfully developing Coenzyme Q10 for the second time in the world.

The company established its presence in Vietnam in 2004 and Indonesia in 2005.

By 2006, Daewoong Pharmaceutical had expanded its reach to China, with the establishment of a new branch, and received the "Family-Friendly Company" award from the Minister of Health and Welfare.

Here's a summary of Daewoong Pharmaceutical's international expansion:

In 2020, Daewoong Pharmaceutical developed a COVID-19 treatment and was selected for a government-funded project.

Daewoong Pharmaceutical is a company that has been around for over 70 years, with a rich history of innovation and growth.

They have a diverse portfolio of products, including prescription medications, over-the-counter drugs, and biopharmaceuticals.

Their research and development efforts have led to the creation of several notable products, such as the anti-wrinkle treatment, KOLYS.

Daewoong Pharmaceutical has a significant presence in the global market, with a presence in over 60 countries.

Their commitment to quality and safety is evident in their adherence to international standards, such as those set by the US FDA.

The company has a strong focus on research and development, with a dedicated team working on new product development and clinical trials.